Following approval by its Executive Committee, the World Anti-Doping Agency (WADA) has now published the revised International Standard for Therapeutic Use Exemptions (ISTUE). This Standard will take effect on 1 January 2010.
The ISTUE was revised as a result of the adoption of the 2010 Prohibited List. The ISTUE had to be amended to accommodate some of the changes to the List to be implemented on 1 January 2010, in particular the removal of inhaled salbutamol from the List. This resulted in the deletion of Annex 1 and of the special provision in relation to Beta-2 agonists of the ISTUE.
Under the 2010 List, salbutamol, salmeterol, platelet-derived preparations, and glucocorticosteroids administered by some routes will require a Declaration of Use. In order to avoid frequent changes to the ISTUE, the name of the substances that require a Declaration of Use is no longer included in the ISTUE, but rather is clearly indicated in the List.
Furthermore, in order to simplify the ISTUE, a number of provisions were rewritten or reordered, maintaining however all the key principles of the Standard.
To consult the revised ISTUE, please visit the new official website of WADA at www.wada-ama.org.